A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
NCT ID: NCT00002330
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
280 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ganciclovir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Topical and ophthalmic nucleoside analogues.
Patients must have:
* HIV positive.
* No more than two episodes of CMV retinitis progression (relapse resulting in reinduction with intravenous anti-CMV therapy) since the original retinitis diagnosis.
* Currently stable retinitis.
Prior Medication:
Allowed:
* Foscarnet prior to the 4 weeks of intravenous induction therapy.
Exclusion Criteria
Patients with the following symptoms or conditions are excluded:
* Persistent or clinically significant diarrhea, nausea, or abdominal pain.
* Severe odynophagia.
* Other gastrointestinal (GI) symptoms or uncontrolled GI disease.
* Active CMV disease of the GI tract (e.g., CMV colitis, CMV esophagitis).
* Ocular media opacities (corneal, lenticular, or vitreal) that prevent ophthalmologic retinal assessments.
* Dementia, decreased mentation, or other encephalopathic signs and symptoms that would preclude informed consent or study compliance.
Concurrent Medication:
Excluded:
* Acyclovir sodium (Zovirax) by any route other than topical.
* Valacyclovir.
* Brovavir.
* Vidarabine.
* Amantadine hydrochloride.
* Cytarabine.
* Idoxuridine.
* Ribavirin.
* Interferon.
* Foscarnet (non-nucleoside pyrophosphate analogue).
* CMV hyperimmune globulin.
* Soluble CD4.
* Trichosanthin (Compound Q).
* Imipenem-cilastatin.
* Isoprinosine.
* Levamisole.
* Other investigational drugs.
Patients with the following prior condition are excluded:
History of hypersensitivity to acyclovir or ganciclovir.
Prior Medication:
Excluded:
* More than three induction regimens with intravenous anti-CMV therapy.
* Any prior oral ganciclovir.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Global Development
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of Alabama at Birmingham / AIDS Outpatient Clinic
Birmingham, Alabama, United States
McDowell Clinic
Phoenix, Arizona, United States
Dr Ken Fisher
Phoenix, Arizona, United States
Univ of Arizona / Health Science Ctr
Tucson, Arizona, United States
East Bay AIDS Ctr
Berkeley, California, United States
AIDS Clinical Research Ctr / UCLA Med Ctr
Los Angeles, California, United States
UCSD Med Ctr / Pediatrics
San Diego, California, United States
Davies Med Ctr
San Francisco, California, United States
Mount Zion Med Ctr / UCSF
San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
San Francisco, California, United States
George Washington Univ Med Ctr
Washington D.C., District of Columbia, United States
Community Research Initiative
Coral Gables, Florida, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
Margo Heath - Chiozzi
Honolulu, Hawaii, United States
Univ of Maryland School of Medicine
Baltimore, Maryland, United States
AIDS Clinical Trials Unit
St Louis, Missouri, United States
HIV Wellness Ctr / Univ Med Ctr
Las Vegas, Nevada, United States
Univ of New Mexico
Albuquerque, New Mexico, United States
AIDS Wellness Clinic
Sante Fe, New Mexico, United States
Dr Dorothy Friedberg
New York, New York, United States
Saint Luke's - Roosevelt Hosp Ctr
New York, New York, United States
New York Hosp - Cornell Med Ctr
New York, New York, United States
Univ of North Carolina School of Medicine
Chapel Hill, North Carolina, United States
Nalle Clinic
Charlotte, North Carolina, United States
Case Western Reserve Univ
Cleveland, Ohio, United States
Ohio State Univ Hosp
Columbus, Ohio, United States
Associates Med and Mental Health
Tulsa, Oklahoma, United States
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, United States
Buckley Braffman Stern Med Associates
Philadelphia, Pennsylvania, United States
Austin Infectious Disease Consultants
Austin, Texas, United States
N Texas Ctr for AIDS & Clin Rsch
Dallas, Texas, United States
Texas Tech Health Sciences Ctr
El Paso, Texas, United States
Dr Daniel Barbero
Fort Worth, Texas, United States
Infectious Diseases Association of Houston
Houston, Texas, United States
Audie L Murphy Veterans Administration Hosp
San Antonio, Texas, United States
Saint Paul's Hosp
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lalezari J, Friedberg D, Bisset J, Giordano M, Hardy D, Robinson C. A comparison of the safety and efficacy of 3g, 4.5g and 6g doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. Int Conf AIDS. 1996 Jul 7-12;11(2):226 (abstract no ThB305)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GANs2226
Identifier Type: -
Identifier Source: secondary_id
059F
Identifier Type: -
Identifier Source: org_study_id